Hyrimoz (adalimumab-adaz)

aBL 761071

Hyrimoz (adalimumab-adaz)

aBL 761071

U.S. License Holder:

Sandoz Inc.

Date of License:

October-30-2018

Last Update:

August-15-2019

approved_indications FDA-Approved Indications

HYRIMOZ (adalimumab-adaz) is a tumor necrosis factor (TNF)-blocker indicated for treatment of:

Rheumatoid Arthritis (RA): Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA;

Juvenile Idiopathic Arthritis (JIA): Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 4 years of age and older;

Psoriatic Arthritis (PsA): Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA;

Ankylosing Spondylitis (AS): Reducing signs and symptoms in adult patients with active AS;

Adult Crohn’s Disease (CD): Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's Disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab;

Ulcerative Colitis (UC): Inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine or 6-mercaptopurine (6-MP). The effectiveness of HYRIMOZ has not been established in patients who have lost response to or were intolerant to TNF-blockers;

Plaque Psoriasis (Ps): The treatment of adult patients with mode rate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.

approved_indications Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In The E.U.

Hyrimoz® (Sandoz) (July-2018)

Biosimilars Approved In Australia

Hyrimoz® (Sandoz) (May-2019)

approved_indications Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

IPR2017-01823

U.S. Patent No.
8,802,100 (Formulation of Human Antibodies for Treating TNF-Alpha Associated Disorders)

Patent Owner
AbbVie Biotechnology Ltd.

Petitioner(s)
Sandoz Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Formulation

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

IPR2017-01824

U.S. Patent No.
9,512,216 (Use of TNF-Alpha Inhibitor)

Patent Owner
AbbVie Biotechnology Ltd.

Petitioner(s)
Sandoz Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

Federal Circuit Appeal(s)
18-2142

IPR Status
IPR Not Instituted; Request for Rehearing Denied; Federal Circuit Appeal Voluntarily Dismissed

IPR2017-01987

U.S. Patent No.
8,911,737 (Methods of Administering Anti-TNF Alpha Antibodies)

Patent Owner
AbbVie Biotechnology Ltd.; Abbott Biotechnology Ltd.

Petitioner(s)
Sandoz Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled while Request for Rehearing of Decision Denying Institution was Pending)

IPR Status
IPR Not Instituted; Request for Rehearing Terminated Due to Settlement

IPR2017-01988

U.S. Patent No.
8,974,790 (Methods of Administering Anti-TNF Alpha Antibodies)

Patent Owner
AbbVie Biotechnology Ltd.; Abbott Biotechnology Ltd.

Petitioner(s)
Sandoz Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled while Request for Rehearing of Decision Denying Institution was Pending)

IPR Status
IPR Not Instituted; Request for Rehearing Terminated Due to Settlement

IPR2017-02105

U.S. Patent No.
9,090,689 (Use of TNF-Alpha Inhibitor for Treatment of Psoriasis)

Patent Owner
AbbVie Biotechnology Ltd.

Petitioner(s)
Sandoz Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled After Institution)

IPR Status
Terminated Due to Settlement After Institution

IPR2017-02106

U.S. Patent No.
9,067,992 (Use of TNF-Alpha Inhibitor for Treatment of Psoriatic Arthritis)

Patent Owner
AbbVie Biotechnology Ltd.

Petitioner(s)
Sandoz Inc.

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Y

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled After Institution)

IPR Status
Terminated Due to Settlement After Institution

IPR2018-00002

U.S. Patent No.
9,512,216 (Use of TNF-Alpha Inhibitor)

Patent Owner
AbbVie Biotechnology Ltd.

Petitioner(s)
Sandoz Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

Federal Circuit Appeal(s)
18-2143 (Consolidated with lead appeal 18-2142)

IPR Status
IPR Not Instituted; Federal Circuit Appeal Voluntarily Dismissed

IPR2018-00156

U.S. Patent No.
9,187,559 (Multiple-Variable Dose Regimen for Treating Idiopathic Inflammatory Bowel Disease)

Patent Owner
AbbVie Biotechnology Ltd.

Petitioner(s)
Sandoz Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

approved_indications U.S. Patent Litigations

PACER

Case No(s):

3:18-cv-12668 (D.N.J.)

U.S. Patent Nos.
9,187,559 (Multiple-Variable Dose Regimen for Treating Idiopathic Inflammatory Bowel Disease) 9,750,808 (Formulation of Human Antibodies for Treating TNF-alpha Associated Disorders)

Plaintiffs
AbbVie Biotechnology Ltd.; AbbVie Inc.

Defendants
Sandoz GmbH; Sandoz Inc.; Sandoz International GmbH

Status
Dismissed due to Settlement

BPCIA
Y

related articles Related News Articles

Spotlight On: Biosimilar Litigations April Breyer Menon; Ha Kung Wong July 31, 2019
Spotlight On: Humira® (adalimumab) / Amjevita™ (adalimumab-atto) / Cyltezo® (adalimumab-adbm) / Hyrimoz™ (adalimumab-adaz) / Hadlima™ (adalimumab-bwwd) April Breyer Menon; Corinne E. Atton; Joseph K. Yarsky; Robert S. Schwartz, Ph.D. July 31, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – October 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. November 12, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – July 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. August 3, 2018

Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

captcha